TrialBreast cancer research and treatment2013

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.

Cynthia X Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.